Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Exelixis's pe ratio was 22.2× on Nov 11, 2026, against 18.6× a year earlier. Over the last 5 years it ranged from 15.4× to 85.7×, with a median of 22.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 22.2× | +3.7 |
| 2025 | Dec 31, 2025 | 18.5× | −2.9 |
| 2024 | Dec 31, 2024 | 21.3× | −64.3 |
| 2023 | Dec 29, 2023 | 85.7× | +68.8 |
| 2022 | Dec 30, 2022 | 16.9× | −19.0 |
| 2021 | Dec 31, 2021 | 35.8× | −6.0 |
| 2020 | Dec 31, 2020 | 41.8× | +32.8 |
| 2019 | Dec 31, 2019 | 9.0× | −7.6 |
| 2018 | Dec 31, 2018 | 16.7× | −45.4 |
| 2017 | Dec 29, 2017 | 62.0× | +52.7 |
| 2012 | Oct 31, 2012 | 9.3× | – |
See a number that looks wrong?